文献速递神经核医学肿瘤 PET/CT

一站式检查:18F-Flortaucipir PET 可区分淀粉样蛋白阳性与阴性的神经退行性疾病

One-Stop Shop: 18F-Flortaucipir PET Differentiates Amyloid-Positive and -Negative Forms of Neurodegenerative Diseases.
PubMed 文献 · J Nucl Med · 2020-07-03

本研究纳入35例淀粉样蛋白阳性神经退行性病变患者、19例淀粉样蛋白阴性患者和17名健康对照,采用数据驱动的缩放子轮廓模型/主成分分析(SSM/PCA)识别18F-flortaucipir PET的空间协方差模式。模式表达强度预测淀粉样蛋白状态的敏感度为0.94、特异度为0.83,基于两个成分的支持向量机分类预测准确率为98%,解剖上淀粉样蛋白阳性患者由顶枕灰质驱动、阴性患者以白质结合为主。作者认为18F-flortaucipir PET单独即可提供相当于淀粉样蛋白PET的附加信息,结合灌注加权早期相采集(等效18F-FDG PET)单次扫描可能涵盖A/T/N全面信息。

要点

  • SSM/PCA模式表达强度预测淀粉样蛋白状态敏感度0.94、特异度0.83。
  • 基于2个SSM/PCA成分表达强度的支持向量机分类预测准确率为98%。
  • 淀粉样蛋白阳性患者由顶枕灰质驱动,阴性患者以白质结合为主。

核心结论

  • SSM/PCA衍生的18F-flortaucipir结合模式能以高准确度区分淀粉样蛋白阳性与阴性的神经退行性疾病。
  • 作者认为18F-flortaucipir PET单独可能传达相当于淀粉样蛋白PET的附加信息。
  • 结合灌注加权早期相采集(等效18F-FDG PET),单次扫描可能包含近期生物标志物分类算法(A/T/N)所需的淀粉样蛋白(A)、tau(T)和神经退行性变(N)状态的全面信息。

研究设计与样本

  • 纳入35例淀粉样蛋白阳性神经退行性病变患者、19例淀粉样蛋白阴性神经退行性病变患者和17名健康对照的18F-flortaucipir PET数据。
  • 采用数据驱动的缩放子轮廓模型(SSM)/主成分分析(PCA)识别空间协方差模式。
  • 在受试者工作特征分析中检验SSM/PCA模式表达强度预测淀粉样蛋白状态的能力,并用留一法验证。

主要发现

  • 模式表达强度预测淀粉样蛋白状态的敏感度为0.94、特异度为0.83。
  • 基于2个不同SSM/PCA成分表达强度的支持向量机分类预测准确率为98%。
  • 解剖上,预测性能由淀粉样蛋白阳性患者的顶枕灰质驱动,而淀粉样蛋白阴性患者以白质结合为主。

关键数值与推荐

  • 18F-flortaucipir PET模式表达强度预测淀粉样蛋白状态:敏感度0.94、特异度0.83。
  • 基于2个SSM/PCA成分表达强度的支持向量机分类预测准确率为98%。

临床怎么用

  • 作者认为18F-flortaucipir PET单独可能传达相当于淀粉样蛋白PET的附加信息。
  • 作者认为结合灌注加权早期相采集(等效18F-FDG PET),单次扫描可能包含A/T/N分类所需的全面信息。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tau protein aggregations are a hallmark of amyloid-associated Alzheimer disease and some forms of non-amyloid-associated frontotemporal lobar degeneration. In recent years, several tracers for in vivo tau imaging have been under evaluation. This study investigated the ability of 18F-flortaucipir PET not only to assess tau positivity but also to differentiate between amyloid-positive and -negative forms of neurodegeneration on the basis of different 18F-flortaucipir PET signatures. Methods: The 18F-flortaucipir PET data of 35 patients with amyloid-positive neurodegeneration, 19 patients with amyloid-negative neurodegeneration, and 17 healthy controls were included in a data-driven scaled subprofile model (SSM)/principal-component analysis (PCA) identifying spatial covariance patterns. SSM/PCA pattern expression strengths were tested for their ability to predict amyloid status in a receiver-operating-characteristic analysis and validated with a leave-one-out approach. Results: Pattern expression strengths predicted amyloid status with a sensitivity of 0.94 and a specificity of 0.83. A support vector machine classification based on pattern expression strengths in 2 different SSM/PCA components yielded a prediction accuracy of 98%. Anatomically, prediction performance was driven by parietooccipital gray matter in amyloid-positive patients versus predominant white matter binding in amyloid-negative patients. Conclusion: SSM/PCA-derived binding patterns of 18F-flortaucipir differentiate between amyloid-positive and -negative neurodegenerative diseases with high accuracy. 18F-flortaucipir PET alone may convey additional information equivalent to that from amyloid PET. Together with a perfusion-weighted early-phase acquisition (18F-FDG PET-equivalent), a single scan potentially contains comprehensive information on amyloid (A), tau (T), and neurodegeneration (N) status as required by recent biomarker classification algorithms (A/T/N).

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hammes J, Bischof GN, Bohn KP, et al. One-Stop Shop: 18F-Flortaucipir PET Differentiates Amyloid-Positive and -Negative Forms of Neurodegenerative Diseases. J Nucl Med. 2020. PMID: 32620704. doi:10.2967/jnumed.120.244061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。